WO2001008639A9 - Siloxane containing macromonomers and dental composites thereof - Google Patents

Siloxane containing macromonomers and dental composites thereof

Info

Publication number
WO2001008639A9
WO2001008639A9 PCT/US2000/020348 US0020348W WO0108639A9 WO 2001008639 A9 WO2001008639 A9 WO 2001008639A9 US 0020348 W US0020348 W US 0020348W WO 0108639 A9 WO0108639 A9 WO 0108639A9
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
unsubstituted
macromonomer
group
macromonomers
Prior art date
Application number
PCT/US2000/020348
Other languages
French (fr)
Other versions
WO2001008639A8 (en
WO2001008639A1 (en
Inventor
Joachim E Klee
Uwe Walz
Juergen Fiedler
Rolf Muelhaupt
Holger Frey
Ekkehardt Mueh
Original Assignee
Dentsply Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dentsply Int Inc filed Critical Dentsply Int Inc
Priority to JP2001513370A priority Critical patent/JP2003505486A/en
Priority to EP00950725A priority patent/EP1200038A1/en
Publication of WO2001008639A1 publication Critical patent/WO2001008639A1/en
Publication of WO2001008639A8 publication Critical patent/WO2001008639A8/en
Publication of WO2001008639A9 publication Critical patent/WO2001008639A9/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00Preparations for dentistry
    • A61K6/80Preparations for artificial teeth, for filling teeth or for capping teeth
    • A61K6/884Preparations for artificial teeth, for filling teeth or for capping teeth comprising natural or synthetic resins
    • A61K6/891Compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A61K6/896Polyorganosilicon compounds

Definitions

  • the volumetric shrinkage is influenced by two different effects: firstly, during polymerization the van der Waals distance of the monomers are replaced by covalent bonds and secondly, the packing density of the polymers increases in comparison to that of the monomers. There are several possibilities to reduce the volumetric shrinkage.
  • Organosiloxanes described by prior art are mono (meth)acrylates having one siloxane moiety (US 5192815), polyfunctional compounds as well as the so-called ORMOCER ® materials (DE 3903407, DE 4133494). Due to the relatively high viscosity of these materials they are only usable in combination with reactive diluents. It is well-known that low-molecular methacrylates are less or rion biocompatibility and have a relatively high volumetric shrinkage.
  • An aim of the invention was to reduce shrinkage by partial or complete replacement of low-molecular polymerizable monomers by the novel siloxane comprising macromonomers.
  • the invention concerns macromonomers of a molecular weight of at least M > 500 g/mol containing at least one siloxane group that are described by the following generally formula:
  • A is a polymerizable moiety, preferably an olefinic double bond, most preferably acrylate or methacrylate, R., is an C, to C 18 oxyalkyl, a C 5 to C 18 oxycycloalkyl or a C 5 to C 15 oxyarylene,
  • C, to C 18 alkyl, a C 5 to C 18 cycloalkyl or a C 5 to C 15 arylor heteroaryl X is N or a substituted or unsubstituted C, to C 18 alkylene, a C, to C 18 oxyalkylene or C, to C 18 carboxyalkylene Y is an C, to C 18 alkylene, C 1 to C 18 oxyalkylene or an urethane -O-CO-NH- linking moiety
  • Z is an C, to C 18 alkylene, a C 5 to C 18 cycloalkylene or a C 5 to C 15 arylene or heteroarylene, n is an integer.
  • the dental/medical composite is usable as a dental restorative material for filling and restoring teeth, making inlays and onlays, as core buildup materials, for artificial teeth, for sealing and coating materials, usable as temporary crown and bridge material.
  • R is a residue derived from a diepoxide, notably a residue of the following formula
  • X is C(CH 3 ) 2 , -CH 2 -, -O-, -S-, -CO-, -SO 2 -
  • Ri denotes hydrogen or a substituted or unsubstituted C, to C 1 ⁇ alkyl, C 5 to C 18 substituted or unsubstituted cycloalkyl, substituted or unsubstituted C 5 to C 18 aryl or heteroaryl,
  • R 2 is a difunctional substituted or unsubstituted C, to C 18 alkylene, C 2 to C 12 alkenyl, C 5 to C 18 substituted or unsubstituted cycloalkylene, C 5 to C 18 arylene or heteroarylene,
  • R 3 denotes a substituted or unsubstituted C, to C 18 alkyl, C 2 to C 12 alkenyl, C 5 to C 18 substituted or unsubstituted cycloalkyl, C 6 to C 12 aryl or C 7 to C 12 aralkyl, or a siloxane moiety I, II or III
  • R 5 is a difunctional substituted or unsubstituted C, to C 18 alkylene, C 2 to C 12 alkenyl, C 5 to C 18 substituted or unsubstituted cycloalkylene, C 5 to C 18 arylene or heteroarylene, preferably CH 2 CH 2 CH 2
  • R 6 denotes a substituted or unsubstituted C, to C 18 alkyl, C 2 to C 12 alkenyl, substituted or unsubstituted C, to C 18 alkylenoxy, C 5 to C 18 substituted or unsubstituted cycloalkyl, C 6 to C 12 aryl or C 7 to C 12 aralkyl,
  • R 4 is a substituted or unsubstituted C 6 to C 12 arylene, such as
  • X is C(CH 3 ) 2 , -CH 2 -, -O-, -S-, -CO-, -SO 2 -,
  • M is a siloxane moiety I, II or III or it is a protection groups forhydroxylic moieties such as an ether, an ester or an urethane group,
  • A is an ether, an ester or an urethane linking group
  • R 5 is a difunctional substituted or unsubstituted C, to C 18 alkylene, C 2 to C 12 alkenyl, C 5 to C 18 substituted or unsubstituted cycloalkylene, C 5 to C 18 arylene or heteroarylene,
  • R 6 denotes a substituted or unsubstituted C, to C 18 alkyl, C 2 to C 12 alkenyl, substituted or unsubstituted C, to C 18 alkylenoxy, C 5 to C 18 substituted or unsubstituted cycloalkyl, C 6 to C 12 aryl or C 7 to C 12 aralkylene, and n is an integer.
  • macromonomers 1 to 3 and 6 to 8 are synthesized in presence of catalysts in substance or in solvents such as THF, toluene, triethyleneglycole bismethacrylate at temperatures between 60 and 100°C.
  • catalysts in substance or in solvents such as THF, toluene, triethyleneglycole bismethacrylate at temperatures between 60 and 100°C.
  • the reaction of macromonomers 4, 5 and 9 - 15 do not require catalysts and occur commonly at 20 to 80 °C.
  • Maromonomers usable in dental/medical compositions comprising at least a macromonomer containing alkylsilyl, alkoxysilyl-, arylsilyl and/or aryloxysilyl groups, a polymerizable monomer, an organic or inorganic acid or a monomer that has at least an acidic moiety, a stabilizer, an initiator, pigments and an organic and/or inorganic filler.
  • a dental/medical composition comprise a macromonomer that is characterized by the following formulas:
  • the polymerizable monomer of the dental/medical compositions is a mono- and polyfunctional (meth)-acrylate, such as a polyalkylenoxide di- and poly-(meth)acrylate, an urethane di- and poly(meth) acrylate, a vinyl-, vinylen- or vinyliden-, acrylate- or methacrylate; preferably were used diethyleneglycol dimethacrylate, triethyleneglycol dimethacrylate, 3,(4),8,(9)- dimethacryloyloxymethyltricyclodecane, dioxolan bismethacrylate, glycerol trimethacrylate, furfuryl methacrylate in a content of 5 to 80 wt-%.
  • a mono- and polyfunctional (meth)-acrylate such as a polyalkylenoxide di- and poly-(meth)acrylate, an urethane di- and poly(meth) acrylate, a vinyl-, vinylen- or vinyl
  • Dental/medical compositions contains a polymerization initiator is a thermal initiator, a redox-initiator or a photo initiator.
  • a dental/medical composition contains a filler that preferably is an inorganic filler and/or an organic filler in an amount of 20 to 85 % (w/w).
  • a dental/medical composition contains a stabilizer, that preferably is a radical absorbing monomer such as hydrochinon monomethylether, hydrochinon dimethylether, BHT, phenothiazine.
  • a stabilizer that preferably is a radical absorbing monomer such as hydrochinon monomethylether, hydrochinon dimethylether, BHT, phenothiazine.
  • a second polymerization reaction occurs using an organic or inorganic acid as a catalyst.
  • organic acids p-toluene sulfonic acid and ascorbic acid are used.
  • the preferred inorganic acids are sulfuric acid or phosphoric acid or organic derivatives of them.
  • pentaerythrol triacrylate monophosphate and dipentaerythol pentaacrylate monophosphate are used.
  • the macromonomers are usable for filler surface modification[CW6].
  • the surface modification of the glass is carried out in an organic solvent such as acetone, THF or toluene or in the absence of any solvents.
  • the surface modification is catalyzed by amines such as primary amines, primary tertiary amines primary secondary amines, secondary amines or tertiary amines or mixtures thereof.
  • amines such as primary amines, primary tertiary amines primary secondary amines, secondary amines or tertiary amines or mixtures thereof.
  • aminopropy triethoxysilane 2-aminoethyl aminopropyl triethoxysilane or triethylamine are used.
  • the new macromonomers are useable as precursors for siloxane condensation products, too. These condensation products containing siloxane linkages and active polymerizable moieties are usable as monomers for dental materials. Furthermore, the new hybrid monomers are usable as precursor for the preparation of nanoparticles containing active polymerizable moieties.
  • the invented ⁇ , ⁇ -methacrylate terminated macromonomers 1 to 9 - 15 or the obtained gels can polymerized using photochemical and radical initiated polymerization.
  • the obtained networks show good mechanical properties, a good adhesion to surfaces of metals, glass and ceramics. Furthermore they show a relative low water absorption. Advantageously is the relative low shrinkage during the polymerization.
  • reaction mixture was extracted twice with 200 ml water, with 150 ml 1 n HCI and with 150 ml 1 n NaHCO 3 and dried over NaSO 4 . Thereafter the toluene was distilled off at 32 mbar and 40 °C and 0.2035g BHT were added.
  • Modified inorganic glass filler (3.0 %):
  • an barium alumo silicate glass having a particle size of 0.9 - 1.5 ⁇ m is dispersed in 250 ml of acetone.
  • 1.5 g of the adduct of 3- aminopropyl-methyl-diethoxysilane/EGAMA is added, 2.0 g of diethylamine and 1.0 g of water are added to the dispersion.
  • the dispersion is stirred at 60° for 6 h.
  • the solvent is evaporated.
  • the remaining solid is stored at 115° for 15 - 18 h under reduced pressure (20 mbar) and sieved through a 220 ⁇ m sieve.
  • the obtained modified glass filler is used in dental/medical composite.
  • 240 g activated resin as described above are mixed with 760 g of modified inorganic glass filler as described above by the use of an planetary mixer under exclusion of daylight.
  • the glass is successively added in five steps of 400 g, 150 g, 100, 50 g and 50 g. After getting a homogeneous paste the mixture is evaporated at a pressure of 180 - 220 mbar. For conditioning the paste is stored under exclusion of daylight for additional 24 h at 40°C.
  • Dental/medical composites obtained according the method described above were tested on their mechanical properties on a standard testing machine (Zwick Z 010).
  • the compressive strength was measured according to the ISO standard 9917, 1991 (dental water based cements), the flexural strength was measured according to ISO 4049, 1988 (dental composite materials).
  • the consistency of the composites were measured as following: To portion 0,5 ml of the composite it is filled into a cylindrical hole of a diameter of 0,7 ml and a height of 1 ,3 mm. The composite is dosed on a surface of a polyetherketone foil and load with a weight of 575 g over a period of 30 sec. Afterwards the diameter of the obtained composite circle is measured in mm and noted as the consistency of the material.
  • the volumetric shrinkage is measured in two different ways. According to the Archimedes method by measuring the change of the density as a result of the polymerization reaction and by measuring the linear dimensional change after the polymerization. The linear dimensional change was afterwards calculated to a volumetric shrinkage (ZH-method). All results are shown in the table below.
  • Figure 1 Transmission electron microscopic photograph of nano- scaled particles.
  • the composite shows a compressive strength of 291.3 MPa a flexural strength of 53 MPa and an E-modulus of 3830 MPa.
  • the volumetric shrinkage is 1.79 % at an degree of conversion of 0.86 (measured by using of DSC).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Plastic & Reconstructive Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dental Preparations (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

The invention concerns macromonomers of a molecular weight of at least M ≥ 500 g/mol containing siloxane groups. The macromonomers are usable as polymerizable monomers in a dental/medical composite comprising further at least a polymerizable monomer, an organic or inorganic acid or an acidic monomer, a stabilizer, an iniator, pigments and an organic or inorganic filler. The dental/medical composite is usable as a dental restorative material for filling and restoring teeth, making inlays and onlays, for artificial teeth, for sealing and surface modification materials, usable as temporary crown and bridge material. Furthermore, the macromonomers are usable for filler surface modification, as precursors for siloxane condensation products or as precursor for preparation of nanoparticles containing active polymerizable moieties.

Description

SILOXANE CONTAINING MACROMONOMERS AND DENTAL COMPOSITES THEREOF
Technical background
In the last decade dental restorative materials, especially dental composites, becomes a high interest. Manly the aesthetic quality of the filling material should be improved in comparison to amalgam and a possible toxicological risking should be avoided.
Presently, commercial dental composites exhibit outstanding mechanical properties, such as compressive strengths ranging from 300 to 500 MPa and flexural strengths ranging from 130 to 170 MPa. Furthermore, over the past years they have been improved with respect to abrasion resistance, marginal integrity, fatigue behavior and their optical properties. Nevertheless, a volumetric shrinkage of about 2.5 to 4.0% takes place during the polymerization of these composites. This shrinkage may lead to marginal gap formation, microfractures in the material and sometimes enamel edge cracks. Secondary caries may arise as a result of these defects. Therefore an important objective is to develop new composite materials that exhibit reduced volumetric shrinkage without sacrificing other beneficial properties.
The volumetric shrinkage is influenced by two different effects: firstly, during polymerization the van der Waals distance of the monomers are replaced by covalent bonds and secondly, the packing density of the polymers increases in comparison to that of the monomers. There are several possibilities to reduce the volumetric shrinkage.
In order to reduce volumetric shrinkage and improve mechanical properties materials that comprises polymerizable moieties and additionally siloxane groups were proposed in the past years. Organosiloxanes described by prior art are mono (meth)acrylates having one siloxane moiety (US 5192815), polyfunctional compounds as well as the so-called ORMOCER® materials (DE 3903407, DE 4133494). Due to the relatively high viscosity of these materials they are only usable in combination with reactive diluents. It is well-known that low-molecular methacrylates are less or rion biocompatibility and have a relatively high volumetric shrinkage.
An aim of the invention was to reduce shrinkage by partial or complete replacement of low-molecular polymerizable monomers by the novel siloxane comprising macromonomers.
Description of the invention
The invention concerns macromonomers of a molecular weight of at least M > 500 g/mol containing at least one siloxane group that are described by the following generally formula:
Figure imgf000003_0001
wherein
A is a polymerizable moiety, preferably an olefinic double bond, most preferably acrylate or methacrylate, R., is an C, to C 18 oxyalkyl, a C5 to C18 oxycycloalkyl or a C5 to C15 oxyarylene,
C, to C18 alkyl, a C5 to C18 cycloalkyl or a C5 to C15 arylor heteroaryl X is N or a substituted or unsubstituted C, to C 18 alkylene, a C, to C 18 oxyalkylene or C, to C18 carboxyalkylene Y is an C, to C18 alkylene, C1 to C18 oxyalkylene or an urethane -O-CO-NH- linking moiety Z is an C, to C18 alkylene, a C5 to C18 cycloalkylene or a C5 to C15 arylene or heteroarylene, n is an integer.
The dental/medical composite is usable as a dental restorative material for filling and restoring teeth, making inlays and onlays, as core buildup materials, for artificial teeth, for sealing and coating materials, usable as temporary crown and bridge material.
Examples of the used macromonomers containing alkoxysilyl groups are given in formulas 1 to 15.
Figure imgf000004_0001
Figure imgf000004_0002
Figure imgf000004_0003
8
Figure imgf000005_0001
9
Figure imgf000005_0002
10
Figure imgf000005_0003
11
Figure imgf000005_0004
Figure imgf000006_0001
wherein
R is a residue derived from a diepoxide, notably a residue of the following formula
Figure imgf000006_0002
whereby X is C(CH3)2, -CH2-, -O-, -S-, -CO-, -SO2-
Ri denotes hydrogen or a substituted or unsubstituted C, to C alkyl, C5 to C18 substituted or unsubstituted cycloalkyl, substituted or unsubstituted C5 to C18 aryl or heteroaryl,
R2 is a difunctional substituted or unsubstituted C, to C18 alkylene, C2 to C12 alkenyl, C5 to C18 substituted or unsubstituted cycloalkylene, C5 to C18 arylene or heteroarylene,
R3 denotes a substituted or unsubstituted C, to C18 alkyl, C2 to C12alkenyl, C5 to C18 substituted or unsubstituted cycloalkyl, C6 to C12 aryl or C7 to C12 aralkyl, or a siloxane moiety I, II or III
Figure imgf000006_0003
R5 is a difunctional substituted or unsubstituted C, to C18 alkylene, C2 to C12 alkenyl, C5 to C18 substituted or unsubstituted cycloalkylene, C5 to C18 arylene or heteroarylene, preferably CH2CH2CH2, R6 denotes a substituted or unsubstituted C, to C18 alkyl, C2 to C12 alkenyl, substituted or unsubstituted C, to C18 alkylenoxy, C5 to C18 substituted or unsubstituted cycloalkyl, C6 to C12 aryl or C7 to C12 aralkyl,
R4 is a substituted or unsubstituted C6 to C12 arylene, such as
Figure imgf000007_0001
wherein X is C(CH3)2, -CH2-, -O-, -S-, -CO-, -SO2-,
M is a siloxane moiety I, II or III or it is a protection groups forhydroxylic moieties such as an ether, an ester or an urethane group,
OR6 R6 R6
— A-R5— Si-OR6 — A-R5— Si-OR6 — A-R5— Si-OR6
OR6 OR6 R6
IV V IV wherein A is an ether, an ester or an urethane linking group,
R5 is a difunctional substituted or unsubstituted C, to C18 alkylene, C2 to C12 alkenyl, C5 to C18 substituted or unsubstituted cycloalkylene, C5 to C18 arylene or heteroarylene,
R6 denotes a substituted or unsubstituted C, to C18 alkyl, C2 to C12 alkenyl, substituted or unsubstituted C, to C18 alkylenoxy, C5 to C18 substituted or unsubstituted cycloalkyl, C6 to C12 aryl or C7 to C12 aralkylene, and n is an integer.
Preferably macromonomers 1 to 3 and 6 to 8 are synthesized in presence of catalysts in substance or in solvents such as THF, toluene, triethyleneglycole bismethacrylate at temperatures between 60 and 100°C. The reaction of macromonomers 4, 5 and 9 - 15 do not require catalysts and occur commonly at 20 to 80 °C.
Maromonomers usable in dental/medical compositions comprising at least a macromonomer containing alkylsilyl, alkoxysilyl-, arylsilyl and/or aryloxysilyl groups, a polymerizable monomer, an organic or inorganic acid or a monomer that has at least an acidic moiety, a stabilizer, an initiator, pigments and an organic and/or inorganic filler.
For example a dental/medical composition comprise a macromonomer that is characterized by the following formulas:
Figure imgf000008_0001
Figure imgf000008_0002
-Si
The polymerizable monomer of the dental/medical compositions is a mono- and polyfunctional (meth)-acrylate, such as a polyalkylenoxide di- and poly-(meth)acrylate, an urethane di- and poly(meth) acrylate, a vinyl-, vinylen- or vinyliden-, acrylate- or methacrylate; preferably were used diethyleneglycol dimethacrylate, triethyleneglycol dimethacrylate, 3,(4),8,(9)- dimethacryloyloxymethyltricyclodecane, dioxolan bismethacrylate, glycerol trimethacrylate, furfuryl methacrylate in a content of 5 to 80 wt-%.
Dental/medical compositions contains a polymerization initiator is a thermal initiator, a redox-initiator or a photo initiator.
Furthermore, a dental/medical composition contains a filler that preferably is an inorganic filler and/or an organic filler in an amount of 20 to 85 % (w/w).
In order to avoid spontaneous polymerization a dental/medical composition contains a stabilizer, that preferably is a radical absorbing monomer such as hydrochinon monomethylether, hydrochinon dimethylether, BHT, phenothiazine.
Due to the siloxane moieties in macromonomers a second polymerization reaction occurs using an organic or inorganic acid as a catalyst. Preferably as organic acids p-toluene sulfonic acid and ascorbic acid are used. The preferred inorganic acids are sulfuric acid or phosphoric acid or organic derivatives of them. Most preferably pentaerythrol triacrylate monophosphate and dipentaerythol pentaacrylate monophosphate are used.
Furthermore, the macromonomers are usable for filler surface modification[CW6]. When the macromonomers are used the surface modification of the glass is carried out in an organic solvent such as acetone, THF or toluene or in the absence of any solvents. The surface modification is catalyzed by amines such as primary amines, primary tertiary amines primary secondary amines, secondary amines or tertiary amines or mixtures thereof. Preferably, as catalyst aminopropy triethoxysilane, 2-aminoethyl aminopropyl triethoxysilane or triethylamine are used.
The new macromonomers are useable as precursors for siloxane condensation products, too. These condensation products containing siloxane linkages and active polymerizable moieties are usable as monomers for dental materials. Furthermore, the new hybrid monomers are usable as precursor for the preparation of nanoparticles containing active polymerizable moieties.
The invented α,ω-methacrylate terminated macromonomers 1 to 9 - 15 or the obtained gels can polymerized using photochemical and radical initiated polymerization. The obtained networks show good mechanical properties, a good adhesion to surfaces of metals, glass and ceramics. Furthermore they show a relative low water absorption. Advantageously is the relative low shrinkage during the polymerization.
Example 1
40.000 g (117.50 mmol) bis-[4-(2,3-epoxypropoxy)phenyl]propane, 52.023 g (235.00 mmol) 3-aminopropyl triethoxysilan, 33.408 g 2,3- (epoxypropoxy) methyl methacrylate and 0.126 g 2,6-di-tert.-butyl-p-cresol were reacted for four hours at 90°C. The obtained methacrylate terminated macromonomer is soluble in organic solvents such as chloroform, DMF and THF. In the IR-spectrum was observed no absorption of epoxide groups at 915 and 3050 cm"1. New absorption's was found at 1720 cm"1 (ester groups) and 3400 cm"1 (OH group).
MJ po) = 1050 g/mol, Tg = 5.0 °C, η (23°C) = 50.4 Pa*s (C53H90016N2Si2), 1067.49 g/mol
Figure imgf000010_0001
Condensation of -Si(OC2Hg)3 groups
To 16.570 g (15.52 mmol) of macromonomer 4A-Si (n=1) dissolved in 80 ml THF were added 0.419 g (23.28 mmol) of water under stirring. The reaction mixture were stirred for additional 20 hours at ambient temperature. Then the solvent and ethanol were removed in vacuum. and the condensation product was dried at 40 °C at 10 mbar. Example 2
50.000 g (225.9 mmol) 3-aminopropyl triethoxy silan, 64.218 g (451.7 mmol) 2,3-(epoxypropoxy) methyl methacrylate and 0.1144 g 2,6-di-tert.- butyl-p-cresol were reacted for four hours at 90°C. The obtained methacrylate terminated macromonomer is soluble in organic solvents such as chloroform, DMF and THF. In the IR-spectrum was observed no absorption of epoxide groups at 915 and 3050 cm"1. New absorption's was found at 1720 cm"1 (ester groups) and 3400 cm"1 (OH group).
(C23H4309NSi), 505.68 g/mol; η (23=C) = 34 mPa*s
Figure imgf000011_0001
Condensation of -Si(OC2Hg)3 groups
To 19.260 g (38.09 mmol) of macromonomer 4A-Si (n=0) dissolved in 80 ml THF were added 1.029 g (57.13 mmol) of water under stirring. The reaction mixture were stirred for additional 20 hours at ambient temperature. Then the solvent and ethanol were removed in vacuum and the condensation product was dried at 40 °C at 8 mbar.
Example 3
A mixture of 50.000 g (0.247 mol) butanediole diglycidylether, 70.289 g (0.494 mol) 2,3-(epoxypropoxy) methyl methacrylate, 109.454 g (0.494 mol) 3-aminopropyltriethoxysilane and 0.230 g 2,6-di-tert.-butyl-p-cresol were reacted for 16 hours at 60°C Yield: 229.97 g (100 %)
To 93.052 g (0.100 mol) of the reaction product were added drop-wise under stirring and cooling 47.750 g (0.401 mol) phenylisocyanate and 0.141 g di-tert.-butylsulfide. Yield: 140.94 g (100 %)
Figure imgf000012_0001
In the IR spectrum of the modified macromonomer4B-Si absorption's at 3325 (NHCO), 1713 (CO), 1600 cm"1 (Ph) were found. Absorption's of OH groups at 3425 and NCO groups at 2272 cm"1 are completely missing.
Example 4
Synthesis of ethyleneglycolacrylatmethacrylat (EGAMA)
In a three-necked bottle equipped with a stirrer, a thermometer and a dropping funnel a mixture of 143.80 g (1.105 mol) of 2-hydroxyethyl methacrylate and 123.00 g (1.216 mol) oftriethylamine were dissolved in 800 ml of toluene. Under cooling (0 - 5 °C) 110.00 g (1.216 mol) of acryloyl chloride dissolved in 100 ml toluene were added during four hours. After standing over night, the precipitate was filtered off and washed twice with 20 ml of toluene. Then the reaction mixture was extracted twice with 200 ml water, with 150 ml 1 n HCI and with 150 ml 1 n NaHCO3 and dried over NaSO4. Thereafter the toluene was distilled off at 32 mbar and 40 °C and 0.2035g BHT were added.
Yield: 156.71 g (77 % of th.); bp. 70°C/ 8 mbar, n = 1.4530 Η NMR (CDCI3)/ppm: 5.48 / 6.30 (1), 1.72 (3), 4.28 (5, 6), 5.73 (8), 6.03 (9) 13C NMR (CDCy/ppm: 126.0 (1), 135.8 (2), 17.6 (3), 165.6 (4), 62.2 (5, 6), 167.1 (7), 128.0 (8), 131.1 (9)
Figure imgf000012_0002
Macromonomer 9-Si (n=0):
20.232 g (109.8 mmol) EGAMA, 12.158 g (54.9 mmol) aminopropyl triethoxysilane and 0.032 g BHT were mixed homogeneously and stirred at room temperature for 12 hours. C^NOnSi, 589.75 g/mol; m/z (FAB-MS) = 590.
Condensation of -Si(OC2H5)3 groups
To 12.000 g (11.57 mmol) of macromonomer 9-Si dissolved in 50 ml THF were added 0.313 g (17.35 mmol) of water under stirring. The reaction mixture were stirred for additional 20 hours at ambient temperature. Then the solvent and ethanol were removed in vacuum and the condensation product was dried at 40 °C at 8 mbar.
Example 5 (Macromonomer 9-Si, n=1)
24.643 g (133.8 mmol) EGAMA and 0.062 g BHT were dissolved in 100 ml methanol. To this mixture 25.600 g (133.8 mmol) aminopropyl triethoxysilane were added at 0 - 5 °C and stirred for 2 hours. Then the methanol was distilled off and the mixture was reacted for a further 24 hours at 23 °C. C42H76N2O16Si2, 921.24 g/mol
Example 6 (Macromonomer 15-Si)
26.777 g (145.4 mmol) EGAMA, 10.000 g (48.5 mmol) 2-aminoethyl aminopropyl methyl dimethoxysilane and 0.037 g BHT were mixed homogeneously and stirred at room temperature for 12 hours. C35H58N2O14Si, 758.93 g/mol; m/z (FAB-MS) = 759, u∞ = 1.4749, η (23 C) = 144 Pa*s.
Application Example 7 - Filler surface modification
1. 3-aminopropyl-methyl-diethoxysilane/EGAMA adduct
In a three-necked flask with a dropping funnel, dimroth cooler, CaCI2-drying tube, thermometer and magnetic stirrer 79.956 g (434.1 mmol) EGAMA and 0.121 g BHT are dissolved in 2 0 ml THF. At a temperature of 0-5°C 41.530 g aminopropyl methyl-diethoxysilane in 25 ml THF are added by dropping over a period of 60 min. Afterwards the solution is stirred at room temperature for additional four hours. The solvent is evaporated under reduced pressure of 8 mmbar and a bath temperature of 40°C. The remaining mixture is stirred for additional 24 h at 23°C and 5 hours at 40°C. The addition product
APDES/EGAMA was characterized by FAB-MS m/z 560, n™ = 1.4600, η (23 C) = 40 mPa*s. C26H45NO10Si, 559.72 g/mol.
2. Modified inorganic glass filler (3.0 %):
50 g of an barium alumo silicate glass having a particle size of 0.9 - 1.5 μm is dispersed in 250 ml of acetone. 1.5 g of the adduct of 3- aminopropyl-methyl-diethoxysilane/EGAMA is added, 2.0 g of diethylamine and 1.0 g of water are added to the dispersion. The dispersion is stirred at 60° for 6 h. The solvent is evaporated. For the silanation the remaining solid is stored at 115° for 15 - 18 h under reduced pressure (20 mbar) and sieved through a 220 μm sieve.
To control the success of the silanation a part of the silanated glass was stirred in acetone for 5 h. The solvent was filtered. The remaining glass was washed with acetone. The solutions were dried and the residue of non bonded silane on the glass was weighted.
20.2 % silane were found in the solution. The remaining 79.8 % were bond to the glass surface. Therefore the glass has a total silane content of 2.4 %
The obtained modified glass filler is used in dental/medical composite.
3. Dental/medical composite resin
28.900 g 2,2-Bis-[p-(2-hydroxy-3-methacryloyloxypropoxy)-phenyl]- propane (Bis-GMA), 31.225 g triethylene glycol dimethacrylate, 31.226 g ethoxylated bisphenol-A-dimethacrylate, 8.198 g hexamethylenediisocyanate, 0.330 g dibutyltindilaurate and 0.100 g BHT are mixed in a 250 ml beaker by stirring at 40°C. The obtained resin is used directly for the preparation of a dental/medical composite.
Activated resin
99.35 g resin as described above, 0.30 g camphor quinone and 0.35 DMABE are mixed in a 250 ml beaker by stirring at 40°C.
4. Dental/medical composite
240 g activated resin as described above are mixed with 760 g of modified inorganic glass filler as described above by the use of an planetary mixer under exclusion of daylight. The glass is successively added in five steps of 400 g, 150 g, 100, 50 g and 50 g. After getting a homogeneous paste the mixture is evaporated at a pressure of 180 - 220 mbar. For conditioning the paste is stored under exclusion of daylight for additional 24 h at 40°C.
5. Properties of dental/medical composites
Dental/medical composites obtained according the method described above were tested on their mechanical properties on a standard testing machine (Zwick Z 010). The compressive strength was measured according to the ISO standard 9917, 1991 (dental water based cements), the flexural strength was measured according to ISO 4049, 1988 (dental composite materials).
The consistency of the composites were measured as following: To portion 0,5 ml of the composite it is filled into a cylindrical hole of a diameter of 0,7 ml and a height of 1 ,3 mm. The composite is dosed on a surface of a polyetherketone foil and load with a weight of 575 g over a period of 30 sec. Afterwards the diameter of the obtained composite circle is measured in mm and noted as the consistency of the material.
The volumetric shrinkage is measured in two different ways. According to the Archimedes method by measuring the change of the density as a result of the polymerization reaction and by measuring the linear dimensional change after the polymerization. The linear dimensional change was afterwards calculated to a volumetric shrinkage (ZH-method). All results are shown in the table below.
Figure imgf000016_0001
Application Example 8 - Condensation to nanoparticles in TGDMA
1g (1 ,8 mmol) addition product of EGAMA and aminopropyl trimethoxysilane were dissolved in 9 g TGDMA. To this solution were added 0,15 g (8,2 mmol) water. Then this mixture and stirred for 14 days at room temperature. The formed particles have an average particle size of 3nm. The Transmission electron microscopic photograph ( Figure 1) show the formed nano-scaled particles. In the IR spectrum double bonds of the methacrylate groups were found at 1720 cm"1.
DESCRIPTION OF THE DRAWING
Figure 1 Transmission electron microscopic photograph of nano- scaled particles.
Figure 2 Transmission electron microscopic photograph of nano- scaled particles.
Figure 3 Element specific image - TEM image of the acid catalyzed condensation product (film on carbon-grid) Application Example 9 - Condensation to nanoparticles
1g (1,8 mmol) addition product of EGAMA and aminopropyl trimethoxysilane were dissolved in 10 ml ethanol. To this solution were added 1.08 g water and 0.51 g of acetic acid and stirred for 14 days at room temperature. The formed particles have an average particle size of 6.6 nm.
In the Element specific image of the Transmission electron microscopic photograph (Figure 4) the silcium atoms of nano-scaled particles were found. These particles were observed in the Transmission electron microscopic photograph (Figure 3), too. In the IR spectrum double bonds of the methacrylate groups were found at 1720 cm"1.
Application Example 9 - Preparation a composite
0.035g camphor quinone and 0.035g dimethylamino benzoic acid ethyl ester were added to 3.00g of the addition product of EGAMA and aminopropyl diethoxymethylsilane and 7.00 g Bis-GMA. To this mixture silanized Spectrum glass (Schott) was added so that composites with about 70% share filler were obtained. Then the composite was homogenized by stirring at 40°C for 30 min and then degassed at 200 mbar and 60°C for 15 min. The photochemical polymerization of these samples was carried out in a Triad photochemical curing unit (Dentsply De Trey, Konstanz) within 4 minutes.
The composite shows a compressive strength of 291.3 MPa a flexural strength of 53 MPa and an E-modulus of 3830 MPa. The volumetric shrinkage is 1.79 % at an degree of conversion of 0.86 (measured by using of DSC).

Claims

We claim:
1. A macromonomers comprising a molecular weight of at least about M > 500 g/mol containing siloxane groups that are characterized by the following formula:
Figure imgf000018_0001
wherein
A is a polymerizable moiety;
Ri is a Ci to C is oxyalkyl, a C5 to C18 oxycycloalkyl or a C5 to Cι5 oxyaryl, Ci to C18 alkyl, a C5 to C18 cycloalkyl or a C5 to C15 aryl or heteroaryl; X is N or a substituted or unsubstituted Ci to C 18 alkylene, a Ci to C 18 oxyalkylene or Ci to C18 carboxyalkylene; Y is a Ci to C18 alkylene, Ci to C18 oxyalkylene or a urethane -O-CO-NH- linking moiety; Z is a Ci to C18 alkylene, a C5 to C18 cycloalkylene or a C5 to C15 arylene or heteroarylene, n is an integer.
2. A macromonomer as in claim 1 , wherein said polymerizable moiety has an olefinic double bond.
3. A macromonomer as in claim 2, wherein said polymerizable moiety is selected from the group consisting of acrylate and methacrylate.
4. A macromonomers comprising:
Figure imgf000019_0001
Figure imgf000019_0002
Figure imgf000020_0001
9
Figure imgf000020_0002
10
Figure imgf000020_0003
11
Figure imgf000020_0004
13
Figure imgf000021_0001
15
wherein
R is a residue derived from a diepoxide and having a formula selected from the group consisting of i, ii, iii, iv as follows:
Figure imgf000021_0002
III
IV whereby X is C(CH3)2, -CH2-, -O-, -S-, -CO-, -SO2-; Ri denotes hydrogen or a substituted or unsubstituted Ci to C18 alkyl, C5 to C18 substituted or unsubstituted cycloalkyl, substituted or unsubstituted C5 to C18 aryl or heteroaryl,
R2 is a difunctional substituted or unsubstituted Ci to C alkylene, C2 to C12 alkenyl, C5 to C18 substituted or unsubstituted cycloalkylene, C5 to C18 arylene or heteroarylene,
R3 denotes a substituted or unsubstituted Ci to C18 alkyl, C2 to Cι2 alkenyl, C5 to C18 substituted or unsubstituted cycloalkyl, C6 to C12 aryl or C7 to C12 aralkyl, or a siloxane moiety I, II or III
Figure imgf000022_0001
I II III
R4 is a substituted or unsubstituted C6 to C12 arylene
R5 is a difunctional substituted or unsubstituted Ci to C18 alkylene, C2 to C12 alkenyl, C5 to C18 substituted or unsubstituted cycloalkylene, C5 to C18 arylene or heteroarylene, preferably CH2CH2CH2,
R6 denotes a substituted or unsubstituted Ci to C18 alkyl, substituted or unsubstituted Ci to C18 alkylenoxy, C2 to C12 alkenyl, C5 to C18 substituted or unsubstituted cycloalkyl, C6 to Cι2 aryl or C7 to C12 aralkyl,
M is a siloxane moiety I, II or III or it is a protection groups for hydroxylic moieties selected from the group consisting of an ether, an ester or a urethane group; R5 is a difunctional substituted or unsubstituted Ci to C18 alkylene, C2 to C12 alkenyl, C5 to C18 substituted or unsubstituted cycloalkylene, C5 to C18 arylene or heteroarylene,
R6 denotes a substituted or unsubstituted Ci to C18 alkyl, C2 to C12 alkenyl, substituted or unsubstituted Ci to C18 alkylenoxy, C5 to Cι8 substituted or unsubstituted cycloalkyl, C6 to C12 aryl or C7 to C12 aralkyl, and n is an integer.
5. A macromolecule as in claim 4, wherein R4 is selected from VII and VIII as follows:
Figure imgf000023_0001
VII VIII wherein X is C(CH3)2, -CH2-, -O-, -S-, -CO-, or, -SO2-.
6. A macromolecule as in claim 4, wherein M is selected from the group consisting of
OR6 e R6 -A-R5— Si-OR6 -A-R5- -Si-OR6 — A-R5— Si-OR6 OR6 OR6 Re IV V IV F|X THIS wherein A is an ether, an ester or an urethane linking group 7. A macromonomer of claims 1 synthesized in presence of catalysts or in solvents selected from the group consisting of THF, toluene and triethyleneglycol bismethacrylate.
8. Macromonomers of claim 1 wherein said macromonomer is characterized by the following formula:
Figure imgf000023_0002
9. Macromonomers of claim 1 wherein said macromonomer is characterized by the following formula:
Figure imgf000024_0001
10. A composition comprising the macromonomer of claim 1 usable a) as monomers in dental composition that further comprises a polymerizable monomer, an organic or inorganic acid or a monomer that has at least an acidic moiety, a stabilizer, an initiator, pigments and an organic or inorganic filler; or b) for filler surface modification or c) as precursor for siloxane condensation products containing active polymerizable moieties d) as precursor for preparation of nanoparticles containing active polymerizable moieties.
11. A composition as in claim 6 comprising at least a macromonomer containing at least one siloxane group, a polymerizable monomer, an organic or inorganic acid or a monomer that has at least an acidic moiety, a stabilizer, an initiator, pigments and an organic and/or inorganic filler.
12. A composition as in claim 11 wherein said polymerizable monomer is a mono- and polyfunctional (meth)acrylate, in a content of 5 to 80 wt-%.
13 A composition as in claim 12, wherein said polymerizable monomer is selected from the group consisting of polyalkylenoxide di- and poly- (meth)acrylate, urethane di- and poly(meth) acrylate, and vinyl-, vinylen- , vinyliden-acrylate- or methacrylate, alkoxysilyl (meth)acrylate.
14 a composition as in claim 13, wherein said polymerizable monomer is selected from the group consisting of diethylene glycol dimethacrylate, triethylene glycol dimethacrylate, 3,(4),8,(9)-dimethacryloyloxymethyltricyclo decane, dioxolan bismethacrylate, glycerol trimethacrylate, and furfuryl methacrylate.
15. A composition as in claim 11 wherein said organic acid is selected from the group consisting of p-toluene sulfonic acid, ascorbic acid, citric acid, and maleic acid.
16. A composition as in claim 11 wherein said acidic polymerizable monomer is selected from the group consisting of pentaerythrol triacrylate monophosphate, dipentaerythrol pentaacrylate monophosphate, methacrylic acid, and acrylic acid.
17. A macromonomer as in claim 1 wherein said polymerization initiator is a thermal initiator, a redox-initiator or a photo initiator.
18. A macromonomer as in claim 17 wherein said photo initiator is chamfer quinone an/or a diaryliodonium salt, a triarylsulfonium salt or a pyridinium salt.
19. A macromonomer as in claim 11 wherein said filler is an inorganic filler and/or an organic filler.
20. A macromonomer as in claim 11 wherein said stabilizer is a radical absorbing monomer such as hydrochinonmonomethylether, hydrochinondimethylether, BHT, phenothiazine.
21. A macromonomer as in claim 11 that is usable as dental restorative material for filling and restoring teeth, making inlays and onlays, as core buildup materials, for artificial teeth, for sealing and surface modification materials or that is usable as temporary crown and bridge material.
22. A macromonomer as in claim 11 that is usable as a temporary crown and bridge material.
23. A macromonomer as in claim 10 that comprises an inorganic or organic filler that is modified using siloxane containing macromonomers of claim 1.
24. Macromonomers of claim 10 usable for filler surface modification that occurs in combination with basic catalysts selected from the group consisting primary amines, primary tertiary amines primary secondary amines, secondary amines, tertiary amines and mixtures thereof in, optionally in the presence of solvents.
25. Macromonomers of claim 10 usable as precursors for siloxane condensation products containing active polymerizable moieties that are applicable as polymerizable monomers for dental material optionally in presence of further hydrolysable compounds of Silicium or Ba, B, Al, Tl, In or other transition element.
PCT/US2000/020348 1999-07-28 2000-07-26 Siloxane containing macromonomers and dental composites thereof WO2001008639A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2001513370A JP2003505486A (en) 1999-07-28 2000-07-26 Siloxane containing macromonomer and their dental compositions
EP00950725A EP1200038A1 (en) 1999-07-28 2000-07-26 Siloxane containing macromonomers and dental composites thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14609399P 1999-07-28 1999-07-28
US60/146,093 1999-07-28
US62620000A 2000-07-26 2000-07-26
US09/626,200 2000-07-26

Publications (3)

Publication Number Publication Date
WO2001008639A1 WO2001008639A1 (en) 2001-02-08
WO2001008639A8 WO2001008639A8 (en) 2001-06-14
WO2001008639A9 true WO2001008639A9 (en) 2002-09-12

Family

ID=26843566

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/020348 WO2001008639A1 (en) 1999-07-28 2000-07-26 Siloxane containing macromonomers and dental composites thereof

Country Status (3)

Country Link
EP (1) EP1200038A1 (en)
JP (1) JP2003505486A (en)
WO (1) WO2001008639A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10101537A1 (en) * 2001-01-15 2002-08-08 Dentsply Detrey Gmbh Process for the preparation of a polymerizable dental composition
DE10206451A1 (en) 2002-02-15 2003-08-28 Dentsply Detrey Gmbh Self-etching, self-priming dental adhesive, e.g. for bonding restorations, comprises an aqueous solution of polymerizable nano-particles made by hydrolysis of organo-siloxane with polymerizable groups and acid groups
DE602005018344D1 (en) * 2004-05-13 2010-01-28 Bluestar Silicones France CATION REACTION NETWORKABLE / POLYMERIZABLE HIGH POLAR STABLE DENTAL COMPOSITION
FR2872408B1 (en) * 2004-06-30 2006-09-08 Rhodia Chimie Sa STABLE AND HIGH CHARGE CATIONIC CROSSLINKABLE / STERILIZABLE DENTAL COMPOSITION
DE102005018351B4 (en) * 2005-04-20 2008-05-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Use of durable, durable composites in the dental field
JP2014240372A (en) * 2013-06-12 2014-12-25 三菱レイヨン株式会社 Silane compounds, silsesquioxane compounds and methods of producing the same, curable compositions, cured products, transparent films and laminates
JPWO2018008580A1 (en) * 2016-07-06 2019-04-25 セメダイン株式会社 Curable composition and product
CN111149058B (en) * 2017-09-22 2024-03-08 东丽株式会社 Transparent photosensitive resin composition and application thereof, photoetching spacer, liquid crystal display device and manufacturing method thereof
EP3727276A2 (en) * 2017-12-21 2020-10-28 3M Innovative Properties Company Inorganic dental fillers including a silane treated surface
CN109431817A (en) * 2018-12-20 2019-03-08 四川华柚医疗器械有限公司 A kind of new type resin tooth and preparation method thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3963771A (en) * 1970-09-02 1976-06-15 Union Carbide Corporation Amine acrylate addition reaction products
US3746738A (en) * 1972-03-28 1973-07-17 Union Carbide Corp Silicon containing polyazimides
DE4011044A1 (en) * 1990-04-05 1991-10-10 Fraunhofer Ges Forschung SILANES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR THE PRODUCTION OF POLYMERISATS AND POLYCONDENSATES
DE4310733A1 (en) * 1993-04-01 1994-10-06 Fraunhofer Ges Forschung Self-curing systems
RU2084456C1 (en) * 1994-03-31 1997-07-20 Владимир Александрович Ковязин Method of synthesis of 3-[n,n-bis-(2-hydroxy-3-methacrylhydroxypropyl)amino]-propyl- -(triethoxy)-silane
DE4416857C1 (en) * 1994-05-13 1995-06-29 Fraunhofer Ges Forschung Hydrolysable and polymerisable silane(s) useful in coating, adhesive and moulding compsns. or composites
DE19619046A1 (en) * 1996-05-02 1997-11-06 Ivoclar Ag Use of a composition as a dental material and dental material
WO1998028307A1 (en) * 1996-12-23 1998-07-02 Sartomer Company, Inc. Free radically polymerizable silane monomers and oligomers and the method for making them
DE19714320A1 (en) * 1997-03-25 1998-10-01 Ivoclar Ag Hydrolyzable and polymerizable vinylcyclopropane silanes
DE19903177C5 (en) * 1999-01-21 2010-09-16 Ivoclar Vivadent Ag Use of materials based on polysiloxanes as dental materials

Also Published As

Publication number Publication date
WO2001008639A8 (en) 2001-06-14
EP1200038A1 (en) 2002-05-02
JP2003505486A (en) 2003-02-12
WO2001008639A1 (en) 2001-02-08

Similar Documents

Publication Publication Date Title
DE19903177C5 (en) Use of materials based on polysiloxanes as dental materials
US6284898B1 (en) Hydrolysable and polymerizable oxetane silanes
US6794520B1 (en) Hydrolyzable and polymerizable silanes based on methylene dithiepane
US5886064A (en) Fine-grained polymerizable compositions flowable under pressure or shear stress
KR0179984B1 (en) Dental filling material
US7589132B2 (en) Dental resins, dental composite materials, and method of manufacture thereof
JP2011515513A (en) Low shrinkage multifunctional SSQ resin
JP5383012B2 (en) Dental material with low polymerization shrinkage
EP2931756A1 (en) Addition-fragmentation oligomers
CA2232960C (en) Hydrolysable and polymerizable oxetane silane
WO2001008639A9 (en) Siloxane containing macromonomers and dental composites thereof
US9839585B2 (en) Free radically curable dental compositions
US11992538B2 (en) Polymerizable dental composition based on condensed silanes
US20030055167A1 (en) Siloxane containing macromonomers and dental composites thereof
AU2004321429A1 (en) Dental composition containing unsaturated carbosilane containing components
US20040167296A1 (en) Siloxane containing macromonomers and dental composites thereof
JP7094165B2 (en) Polymeric material containing silane-based mobile reagents
US20040131995A1 (en) Process for the preparation of a polymerizable dental composition
US7101942B2 (en) Dental materials based on metal oxide clusters
US6569917B1 (en) Dental materials based on polysiloxanes
JP6614998B2 (en) Dental curable composition
KR101799003B1 (en) Catechol derivative-based adhesive composition and method for preparing the same
JP4230700B2 (en) Dental materials based on metal oxide clusters
US20080237907A1 (en) Process for the preparation of a polymerizable dental composition
DE29924636U1 (en) Dental material, useful as compound, cement, filling material, bonding or coating, contains polysiloxane based on silane with (alkyl)acrylated alkyl- or acyl-aminoalkyl group

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP SE

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): JP SE

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 06/2001 UNDER (30) REPLACE "NOT FURNISHED" BY "09/626200"

WWE Wipo information: entry into national phase

Ref document number: 2000950725

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000950725

Country of ref document: EP

AK Designated states

Kind code of ref document: C2

Designated state(s): JP SE

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1-17, DESCRIPTION, REPLACED BY NEW PAGES 1-16; PAGES 18-26, CLAIMS, REPLACED BY NEW PAGES 17-25; PAGE 1/1, DRAWINGS, ADDED; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWW Wipo information: withdrawn in national office

Ref document number: 2000950725

Country of ref document: EP